Drug Database
Back to search

Netherlands· NL-d40af110368c

Eptifibatide AFTPharm 0,75 mg/ml oplossing voor infusie

A eptifibatide product containing eptifibatide, registered in Netherlands by AFT Pharmaceuticals (EUR) Limited. The same ATC class is registered in 15 of our 19 countries.

ATC B01AC16

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEptifibatide AFTPharm 0,75 mg/ml oplo…ATCB01AC16REGISTER NO.NL-d40af110368cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about eptifibatideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Eptifibatide is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AC16 (eptifibatide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search eptifibatide products by name

Eptifibatide · ATC B01AC16

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
EPTIFIBATIDE
Manufacturer
AFT Pharmaceuticals (EUR) Limited
Country
Netherlands (NL)
ATC code
B01AC16
ATC class
Eptifibatide
Defined daily dose
0.2 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    120246

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

203 interactions on record for eptifibatide.

Graded by severity as the source publishes them — 62 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check eptifibatide against other medicinesHow interaction checks work

Eptifibatide · interactions on record

203 records

  • 62 severe
  • 76 moderate
  • 65 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eptifibatide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eptifibatide products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Bulgaria · Ептифибатид Ромфарм
  • Germany · Eptifibatid, Eptifibatid Altamedics
  • Denmark · Eptifibatide "ctruz"
  • Finland · Eptifibatide Ctruz
  • United Kingdom (Northern Ireland) · Eptifibatide Kensington Pharma
  • Hungary · Eptifibatide Rompharm
  • Ireland · Eptifibatide Jed
  • Iceland · Eptifibatide Accord
  • Italy · Eptifibatide Alida
  • Liechtenstein · Eptifibatide Accord
  • Norway · Eptifibatide Accord, Eptifibatide Ctruz
  • Romania · Eptifibatidă Rompharm
  • Sweden · Eptifibatide Ctruz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e4e83987-b4a2-44d9-936f-447dfa53e0b3
GET /v1/drugs/e4e83987-b4a2-44d9-936f-447dfa53e0b3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h120246_smpc.pdf",
  "strength": null,
  "atc_label": "Eptifibatide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg120246",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "EPTIFIBATIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h120246.pdf",
  "authorised_at": "2018/02/01",
  "procedure_number": "NL/H/3888/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "120246",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about eptifibatide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console